Heron Therapeutics Inc (NASDAQ:HRTX) has a beta value of 1.60 and has seen 0.45 million shares traded in the recent trading session. The company, currently valued at $263.12M, closed the recent trade at $1.73 per share which meant it lost -$0.06 on the day or -3.35% during that session. The HRTX stock price is -127.17% off its 52-week high price of $3.93 and 39.88% above the 52-week low of $1.04. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.73 million shares traded. The 3-month trading volume is 3.14 million shares.
The consensus among analysts is that Heron Therapeutics Inc (HRTX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.03.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Sporting -3.35% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the HRTX stock price touched $1.73 or saw a rise of 5.46%. Year-to-date, Heron Therapeutics Inc shares have moved 13.07%, while the 5-day performance has seen it change 14.57%. Over the past 30 days, the shares of Heron Therapeutics Inc (NASDAQ:HRTX) have changed 0.58%. Short interest in the company has seen 29.98 million shares shorted with days to cover at 5.27.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 75.29% from the levels at last check today.. The projected low price target is $5.0 while the price target rests at a high of $9.0. In that case, then, we find that the latest price level in today’s session is -420.23% off the targeted high while a plunge would see the stock gain -189.02% from the levels at last check today..
Heron Therapeutics Inc (HRTX) estimates and forecasts
Figures show that Heron Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -41.06% over the past 6 months, with this year growth rate of 83.75%, compared to 16.70% for the industry. Revenue growth from the last financial year stood is estimated to be 10.88%.
3 analysts offering their estimates for the company have set an average revenue estimate of 37.37M for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 20.01% over the past 5 years. Earnings growth for 2025 is a modest 83.89% while over the next 5 years, the company’s earnings are expected to increase by 47.50%.
HRTX Dividends
Heron Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
Insiders own 0.71% of the company shares, while shares held by institutions stand at 81.35% with a share float percentage of 81.93%. Investors are also buoyed by the number of investors in a company, with Heron Therapeutics Inc having a total of 215.0 institutions that hold shares in the company. The top two institutional holders are RUBRIC CAPITAL MANAGEMENT LP with over 26.71 million shares worth more than $93.5 million. As of 2024-06-30, RUBRIC CAPITAL MANAGEMENT LP held 17.6678% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 8.62 million shares as of 2024-06-30. The firm’s total holdings are worth over $30.16 million and represent 5.6984% of shares outstanding.
